Literature DB >> 3399432

Early treatment of patent ductus arteriosus in premature infants with severe respiratory distress syndrome.

G Pongiglione1, M Marasini, G Silvestri, P Tuo, D Ribaldone, A Bertolini, L Garello-Cantoni.   

Abstract

In 1983, a US National Collaborative Study (NCS) proposed criteria for the diagnosis of hemodynamically significant patent ductus arteriosus (PDA) in premature infants with respiratory distress syndrome (RDS), but the widespread use of pulsed Doppler cross-sectional echocardiography (PD-CSE) in neonatal intensive care units has made direct assessment of the ductus possible thus providing more timely therapy. We have compared the results in 30 premature infants with severe RDS, assessed according to the guidelines of the US NCS, with those in 51 infants whose PDA was diagnosed by PD-CSE. Together with a significant reduction in the age at treatment (7.8 +/- 3.9 vs 2.4 +/- 1.1 days), there was a reduced dependence on artificial ventilation (14.8 +/- 11.0 vs 7.8 +/- 2.7 days), a reduction in the number requiring surgical ligation of PDA (9 vs 2), a decreased incidence of bronchopulmonary-dysplasia (BPD) (40% vs 16%), and a reduction of unfavorable outcome of treatment (death or BPD) (76% vs 49%).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3399432     DOI: 10.1007/BF02083706

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  18 in total

1.  Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia.

Authors:  W H Northway; R C Rosan; D Y Porter
Journal:  N Engl J Med       Date:  1967-02-16       Impact factor: 91.245

2.  Timing of indomethacin therapy in persistent ductus.

Authors:  J Firth; D Pickering
Journal:  Lancet       Date:  1980-07-19       Impact factor: 79.321

3.  The contribution of PDA in the neonate with severe RDS.

Authors:  J Jacob; L Gluck; T DiSessa; D Edwards; M Kulovich; J Kurlinski; T A Merritt; W F Friedman
Journal:  J Pediatr       Date:  1980-01       Impact factor: 4.406

4.  The silent ductus arteriosus.

Authors:  R L McGrath; G A McGuinness; G L Way; R R Wolfe; J J Nora; M A Simmons
Journal:  J Pediatr       Date:  1978-07       Impact factor: 4.406

5.  Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus--a double-blind controlled study.

Authors:  T F Yeh; J A Luken; A Thalji; D Raval; I Carr; R S Pildes
Journal:  J Pediatr       Date:  1981-01       Impact factor: 4.406

6.  Evaluation of the preterm infant for patent ductus arteriosus.

Authors:  R C Ellison; G J Peckham; P Lang; N S Talner; T J Lerer; L Lin; K J Dooley; A S Nadas
Journal:  Pediatrics       Date:  1983-03       Impact factor: 7.124

7.  Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study.

Authors:  W M Gersony; G J Peckham; R C Ellison; O S Miettinen; A S Nadas
Journal:  J Pediatr       Date:  1983-06       Impact factor: 4.406

8.  Increased shunt through the patent ductus arteriosus after surfactant replacement therapy.

Authors:  R I Clyman; A Jobe; M Heymann; M Ikegami; C Roman; B Payne; F Mauray
Journal:  J Pediatr       Date:  1982-01       Impact factor: 4.406

9.  Exogenous human surfactant for treatment of severe respiratory distress syndrome: a randomized prospective clinical trial.

Authors:  M Hallman; T A Merritt; A L Jarvenpaa; B Boynton; F Mannino; L Gluck; T Moore; D Edwards
Journal:  J Pediatr       Date:  1985-06       Impact factor: 4.406

10.  Pulsed Doppler flow characteristics of ductus arteriosus in infants with associated congenital anomalies of the heart or great arteries.

Authors:  J L Cloez; K Isaaz; C Pernot
Journal:  Am J Cardiol       Date:  1986-04-01       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.